Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Alumis has raised $345.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Alumis's investors include General Atlantic, Cormorant Asset Management, Lilly Asia Ventures, Samsara BioCapital, Foresite Capital.
Alumis is headquartered in San Francisco, United States.
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Alumis is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alumis — Funding & Investors." VCBacked, January 7, 2026, https://www.vcbacked.co/company/alumis. Accessed November 13, 2026.
VCBacked. (2026). Alumis — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/alumis
{{cite web |title=Alumis — Funding & Investors |url=https://www.vcbacked.co/company/alumis |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Alumis? Request a listing update